Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTC21C plus bortezomib, lenalidomide and dexamethasone vs VRd in transplant-ineligible newly diagnosed multiple myeloma
CTR20254732Phase 3Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of SCTC21C in multiple myeloma (MM) (2 arms), sponsored by Sinocelltech Group Limited. Started Dec 2025; status: active.
02
Drugs
SCTC21C
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20254732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254732.